DC 853
Alternative Names: DC-853Latest Information Update: 23 Jul 2024
At a glance
- Originator DICE Therapeutics
- Class Antipsoriatics; Small molecules
- Mechanism of Action Interleukin 17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Immunological disorders; Psoriasis
Most Recent Events
- 16 Jul 2024 DICE Therapeutics plans a phase I trial for Healthy volunteers in USA (PO) (NCT06503679)
- 03 Apr 2024 Phase-I clinical trials in Psoriasis (Combination therapy, In adults, In volunteers) in USA (PO) (NCT06345794)
- 03 Apr 2024 Phase-I clinical trials in Psoriasis (Monotherapy, In adults, In volunteers) in USA (PO) (NCT06345794)